<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26034513</article-id><article-id pub-id-type="pmc">4450486</article-id><article-id pub-id-type="publisher-id">114</article-id><article-id pub-id-type="doi">10.1186/s13195-015-0114-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Cerebrospinal fluid amyloid-&#x003b2; 42/40 ratio in clinical setting of memory centers: a multicentric study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Dumurgier</surname><given-names>Julien</given-names></name><address><email>julien.dumurgier@inserm.fr</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Schraen</surname><given-names>Susanna</given-names></name><address><email>susanna.schraen@inserm.fr</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Gabelle</surname><given-names>Audrey</given-names></name><address><email>a-gabelle@chu-montpellier.fr</email></address><xref ref-type="aff" rid="Aff5"/><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Vercruysse</surname><given-names>Olivier</given-names></name><address><email>oliviervercruysse@hotmail.fr</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Bombois</surname><given-names>St&#x000e9;phanie</given-names></name><address><email>stephanie.bombois@chru-lille.fr</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Laplanche</surname><given-names>Jean-Louis</given-names></name><address><email>jean-louis.laplanche@lrb.aphp.fr</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Peoc&#x02019;h</surname><given-names>Katell</given-names></name><address><email>katell.peoch@lrb.aphp.fr</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Sablonni&#x000e8;re</surname><given-names>Bernard</given-names></name><address><email>bernard.sablonniere@inserm.fr</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Kastanenka</surname><given-names>Ksenia V</given-names></name><address><email>kkastanenka@mgh.harvard.edu</email></address><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Delaby</surname><given-names>Constance</given-names></name><address><email>c-delaby@chu-montpellier.fr</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Pasquier</surname><given-names>Florence</given-names></name><address><email>florence.pasquier@chru-lille.fr</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Touchon</surname><given-names>Jacques</given-names></name><address><email>j-touchon@chu-montpellier.fr</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Hugon</surname><given-names>Jacques</given-names></name><address><email>jacques.hugon@inserm.fr</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Paquet</surname><given-names>Claire</given-names></name><address><email>claire.paquet@inserm.fr</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Lehmann</surname><given-names>Sylvain</given-names></name><address><email>s-lehmann@chu-montpellier.fr</email></address><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Centre M&#x000e9;moire Ressources Recherche (CM2R), Paris Nord Ile-de-France, Saint Louis, Lariboisi&#x000e8;re, Fernand-Widal Hospital, AP-HP, 200 rue du Faubourg Saint-Denis, 75010 Paris, France </aff><aff id="Aff2"><label/>INSERM U942, Biomarkers in CardioNeuroVascular diseases (Bio-CANVAS), University of Paris 7-Denis Diderot, Paris, France </aff><aff id="Aff3"><label/>Inserm, UMR 1172, JPArc, Facult&#x000e9; de M&#x000e9;decine, Universit&#x000e9; de Lille, 59045 Lille, France </aff><aff id="Aff4"><label/>Centre de Biologie-Pathologie, Centre Hospitalier R&#x000e9;gional Universitaire, 59037 Lille, France </aff><aff id="Aff5"><label/>Centre M&#x000e9;moire Ressources Recherche de Montpellier, Universit&#x000e9; de Montpellier, Montpellier, France </aff><aff id="Aff6"><label/>Biochimie-Prot&#x000e9;omique Clinique - IRB - CCBHM, INSERM U1040, Universit&#x000e9; de Montpellier, Montpellier, France </aff><aff id="Aff7"><label/>Centre M&#x000e9;moire Ressources Recherche, EA 1046, Centre Hospitalier R&#x000e9;gional Universitaire de Lille, Lille, France </aff><aff id="Aff8"><label/>Service de Biochimie et Biologie Mol&#x000e9;culaire, H&#x000f4;pitaux universitaires Saint-Louis, Lariboisi&#x000e8;re, Fernand-Widal, Assistance Publique-H&#x000f4;pitaux de Paris (AP-HP), PRES Sorbonne Paris Cit&#x000e9;, Paris, France </aff><aff id="Aff9"><label/>Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129 USA </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>7</volume><issue>1</issue><elocation-id>30</elocation-id><history><date date-type="received"><day>10</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>5</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Dumurgier et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>The cerebrospinal fluid (CSF) biomarkers amyloid-&#x003b2; (A&#x003b2;), tau and phosphorylated tau (p-tau181) are now used for the diagnosis of Alzheimer&#x02019;s disease (AD). A&#x003b2;40 is the most abundant A&#x003b2; peptide isoform in the CSF, and the A&#x003b2; 42/40 ratio has been proposed to better reflect brain amyloid production. However, its additional value in the clinical setting remains uncertain.</p></sec><sec><title>Methods</title><p>A total of 367 subjects with cognitive disorders who underwent a lumbar puncture were prospectively included at three French memory centers (Paris-North, Lille and Montpellier; the PLM Study). The frequency of positive, negative and indeterminate CSF profiles were assessed by various methods, and their adequacies with the diagnosis of clinicians were tested using net reclassification improvement (NRI) analyses.</p></sec><sec><title>Results</title><p>On the basis of local optimum cutoffs for A&#x003b2;42 and p-tau181, 22% of the explored patients had indeterminate CSF profiles. The systematic use of A&#x003b2; 42/40 ratio instead of A&#x003b2;42 levels alone decreased the number of indeterminate profiles (17%; <italic>P</italic>&#x02009;=&#x02009;0.03), but it failed to improve the classification of subjects (NRI&#x02009;=&#x02009;&#x02212;2.1%; <italic>P</italic>&#x02009;=&#x02009;0.64). In contrast, the use of A&#x003b2; 42/40 ratio instead of A&#x003b2;42 levels alone in patients with a discrepancy between p-tau181 and A&#x003b2;42 led to a reduction by half of the number of indeterminate profiles (10%; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and was further in agreement with clinician diagnosis (NRI&#x02009;=&#x02009;10.5%; <italic>P</italic>&#x02009;=&#x02009;0.003).</p></sec><sec><title>Conclusions</title><p>In patients with a discrepancy between CSF p-tau181 and CSF A&#x003b2;42, the assessment of A&#x003b2; 42/40 ratio led to a reliable biological conclusion in over 50% of cases that agreed with a clinician&#x02019;s diagnosis.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13195-015-0114-5) contains supplementary material, which is available to authorized users.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Dementia is a growing public health concern in aging populations. The number of people affected worldwide is set to reach 66 million by 2030 [<xref ref-type="bibr" rid="CR1">1</xref>]. Alzheimer&#x02019;s disease (AD) is the most frequent cause of dementia in the elderly. Clinical diagnosis is based on the presence of clinical symptoms, marked by a gradual onset of dementia in the presence of cognitive decline, when other putative disorders have been excluded [<xref ref-type="bibr" rid="CR2">2</xref>]. Unfortunately, the accuracy of AD diagnosis based solely on clinical observation is associated with poor specificity. In most studies comparing clinical diagnosis with neuropathological findings, researchers have reported specificity lower than 70% [<xref ref-type="bibr" rid="CR3">3</xref>]. Development of specific disease-modifying drugs and early diagnosis require an improvement in the accuracy of AD diagnosis.</p><p>The use of biomarkers has strengthened the link between clinical dementia and AD pathophysiology [<xref ref-type="bibr" rid="CR2">2</xref>]. Currently, cerebrospinal fluid (CSF) biomarkers are commonly used in specialized memory clinics [<xref ref-type="bibr" rid="CR4">4</xref>]. A characteristic feature of AD progression is a reduction in amyloid-&#x003b2; (A&#x003b2;) protein (that is, low CSF A&#x003b2;42 level) and an increase of neuronal degeneration biomarkers (that is, increase of CSF total tau and phosphorylated tau (p-tau181) levels) in CSF of subjects with AD [<xref ref-type="bibr" rid="CR5">5</xref>]. The decrease in CSF A&#x003b2;42 levels appears to be an early phenomenon in AD progression and is evident over two decades prior to the first clinical sign [<xref ref-type="bibr" rid="CR6">6</xref>]. Unfortunately, because CSF A&#x003b2;42 levels can also be low in non-AD patients, this biomarker alone is of limited use in a clinical setting [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>]. The limited use of CSF biomarkers can lead to indeterminate results, revealing abnormal tau protein values and normal A&#x003b2; peptide levels or the inverse [<xref ref-type="bibr" rid="CR2">2</xref>]. Furthermore, CSF biomarker results are also characterized by a large intersite variability [<xref ref-type="bibr" rid="CR7">7</xref>] that requires the use of internally validated cutoff levels for each laboratory [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>A&#x003b2;40 is the most abundant A&#x003b2; peptide isoform in the CSF. Compared with CSF A&#x003b2;42 levels alone, A&#x003b2; 42/40 ratio is suggested to account for the constitutive interindividual differences in total CSF A&#x003b2; peptide load between high- and low-amyloid-producing individuals [<xref ref-type="bibr" rid="CR10">10</xref>]. The A&#x003b2; 42/40 ratio could also play an important role in Alzheimer&#x02019;s disease pathogenesis [<xref ref-type="bibr" rid="CR11">11</xref>]. However, the added value of the CSF A&#x003b2;40 level assessment remains controversial [<xref ref-type="bibr" rid="CR12">12</xref>-<xref ref-type="bibr" rid="CR15">15</xref>]. Recently, in a monocentric study, researchers reported that CSF A&#x003b2; 42/40 ratio may be of particular use in patients with ambiguous CSF results [<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, the goal of our present study was to assess CSF A&#x003b2; 42/40 ratios and CSF A&#x003b2;42 levels alone to discriminate AD from non-AD patients in a large, prospective, multicentric population of patients. We hypothesized that the use of A&#x003b2; 42/40 ratio would reduce the frequency of inconclusive CSF results and would lead to a valid AD diagnosis.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Subjects</title><p>According to national recommendations, CSF analyses are routinely used during testing of patients with cognitive disorders in French memory centers [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR17">17</xref>]. Patients were recruited between 1 September 2012 and 1 September 2013 from three French clinical and research memory centers specializing in the care of patients with cognitive disorders. These three centers are based in Paris, Lille and Montpellier (the PLM Study) [<xref ref-type="bibr" rid="CR18">18</xref>-<xref ref-type="bibr" rid="CR20">20</xref>]. All patients who were prospectively included in the study had cognitive disorders and received a lumbar puncture. Patients with unknown clinical diagnoses were excluded. Patients with mild cognitive impairment (MCI) represented a heterogeneous group, including patients with and without AD-related brain lesions, and thus were excluded from this study.</p><p>All patients had a thorough examination, including clinical and neuropsychological evaluations, biological measurements and brain imaging. Patients with AD were included according to the criteria for probable AD as defined by the National Institute on Aging-Alzheimer&#x02019;s Association [<xref ref-type="bibr" rid="CR2">2</xref>]. On the basis of all available elements, which included the results for CSF biomarkers, patients were classified into two groups: AD and non-AD. Complex or unclear cases were discussed, and diagnoses were made by a multidisciplinary team of neurologists, geriatricians and neuropsychologists. Non-AD subjects included subjects with cognitive disorders other than AD (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>), such as frontotemporal dementia, Lewy body disease, Parkinson&#x02019;s disease, Creutzfeldt-Jakob disease and non-degenerative dementia (that is vascular dementia, alcohol-related dementia, normal pressure hydrocephalus, infectious disease and psychiatric disorders) [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>This research study was approved by the local ethics committees of each hospital (see Additional file <xref rid="MOESM2" ref-type="media">2</xref>). All patients agreed to CSF collection, assessments and analyses by providing a written informed consent.</p></sec><sec id="Sec4"><title>Cerebrospinal fluid analysis</title><p>Lumbar punctures were performed on fasting patients within 1 month following their clinical diagnosis, usually between 9:00 am and 12:00 <sc>pm</sc>. In an effort to reduce the intersite variability in CSF readings previously reported [<xref ref-type="bibr" rid="CR7">7</xref>], all three centers used a common 10-ml polypropylene tube to collect the CSF (catalog number 62.610.201; Sarstedt, N&#x000fc;mbrecht, Germany) [<xref ref-type="bibr" rid="CR21">21</xref>]. Each CSF sample was transferred at 4&#x000b0;C to the corresponding local laboratory within 4 hours after collection and was then centrifuged at 1,000 <italic>g</italic> for 10 minutes at 4&#x000b0;C. A small amount of CSF was used to perform routine analyses, including total cell count, bacteriological examination and total protein and glucose levels. The CSF was aliquoted in 0.5-ml polypropylene tubes and stored at &#x02212;80&#x000b0;C to await further analysis. CSF A&#x003b2;40, A&#x003b2;42, total tau and p-tau181 were measured in each local laboratory using a commercially available sandwich enzyme-linked immunosorbent assay (INNOTEST; Fujirebio Europe NV, Gent, Belgium) according to the manufacturer&#x02019;s instructions. Concentrations of total tau greater than 1,200 pg/ml were well above the detection limit and thus were not recalculated after dilution because of the constraints in the procedure. The biological teams involved in CSF analyses were blinded to the clinical diagnoses.</p></sec><sec id="Sec5"><title>Cerebrospinal fluid cutoff determination and interpretation</title><p>CSF cutoffs used in the analyses were determined on the basis of the population included in the present study. We computed both overall and local cutoff receiver operating characteristic (ROC) curves using STATA software (v10, StataCorp, College Station, TX, USA). ROC curves were built for each biomarker by plotting sensitivity and 1&#x02009;&#x02212;&#x02009;specificity to discriminate AD from non-AD patients. Optimum cutoff values were determined using two methods: the highest Youden index (that is, sensitivity&#x02009;+&#x02009;specificity&#x02009;&#x02212;&#x02009;1) and lowest distance between ROC plot and point (0.1). We checked that both approaches led to similar findings, and the presented results correspond to the highest Youden index. STATA code used for the determination of optimum cutoff is detailed in the Additional file <xref rid="MOESM3" ref-type="media">3</xref>.</p><p>CSF results were defined as negative (that is, CSF p-tau181 below cutoff and CSF A&#x003b2;42 above cutoff) or positive (that is, CSF p-tau181 above cutoff and CSF A&#x003b2;42 below cutoff). An indeterminate CSF profile was defined by the association of one positive biomarker and one negative biomarker.</p><p>We chose to evaluate tau pathology based on CSF p-tau181 levels alone because p-tau181 and total tau levels were highly correlated in our sample (Pearson&#x02019;s correlation coefficient&#x02009;=&#x02009;0.87). Furthermore, p-tau181 has previously been reported to be more discriminant than total tau [<xref ref-type="bibr" rid="CR22">22</xref>]. Analyses based on total tau led to findings and conclusions similar to those obtained with p-tau181.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p>The subjects&#x02019; characteristics are presented overall, by diagnosis (AD vs. non-AD) and by CSF collection centers. The various groups (diagnoses, centers) were compared using analysis of variance for continuous variables and &#x003c7;<sup>2</sup> test for categorical variables.</p><p>We computed ROC curves to evaluate the capacity of each CSF biomarker to discriminate AD from non-AD subjects. Analyses were performed in the overall study population and then stratified by centers. Optimum cutoffs for each biomarker were defined using the highest Youden index to discriminate in the best possible manner AD from non-AD subjects, thus maximizing sensitivity and specificity of the analyses based on ROC curve analyses. Then we used local optimum cutoffs for further analysis because intersite differences were present.</p><p>To evaluate the interest of ratio A&#x003b2; 42/40 versus CSF A&#x003b2;42 alone, we compared three methods to interpret CSF results:<list list-type="order"><list-item><p><italic>Method 1</italic>: interpretation based on CSF p-tau181 and on CSF A&#x003b2;42</p></list-item><list-item><p><italic>Method 2</italic>: interpretation based on CSF p-tau181 and on A&#x003b2; 42/40 ratio</p></list-item><list-item><p><italic>Method 3</italic>: a decisional algorithm based, in a first step, on CSF p-tau181 and on CSF A&#x003b2;42. Then, in case of discrepancy between p-tau181 and A&#x003b2;42, we used, in a second step, the A&#x003b2; 42/40 ratio in place of A&#x003b2;<sub>1&#x02013;42</sub></p></list-item></list></p><p>For all three methods, we first determined the percentage of AD, non-AD and indeterminate biological CSF profiles. Proportions of indeterminate profiles according to the methods were compared using the McNemar test. Then we used a net reclassification improvement (NRI) method to compare method 2 to method 1, and method 3 to method 1, among AD patients and non-AD patients (based on clinical diagnosis). Briefly, NRI is a statistical tool used to assess improvement in model performance offered by a new method of classification compared with a reference method [<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref>]. The NRI compares the frequency of appropriate reclassification to inappropriate reclassification with the use of a new model of classification. The NRI is based on reclassification tables constructed separately for participants with or without the interest event (that is, diagnosis of AD or non-AD) and quantifies the correct movement in categories, up for events and down for non-events. Upward movement (up) is a change into a higher category, and downward movement (down) is a change into a lower category based on the new algorithm. The NRI is calculated as follows:</p><p>NRI&#x000a0;=&#x000a0;<italic>P</italic>&#x000a0;(up&#x000a0;|&#x000a0;event)&#x000a0;&#x02010;&#x000a0;<italic>P</italic>&#x000a0;(down&#x000a0;|&#x000a0;event)&#x000a0;+&#x000a0;<italic>P</italic>&#x000a0;(down&#x000a0;|&#x000a0;non&#x02009;&#x02010;&#x02009;event)&#x000a0;&#x02010;&#x000a0;<italic>P</italic>&#x000a0;(up&#x000a0;|&#x000a0;non&#x02009;&#x02010;&#x02009;event) [<xref ref-type="bibr" rid="CR23">23</xref>]</p><p>The null hypothesis for NRI&#x02009;=&#x02009;0 was tested using Z-statistics following McNemar asymptotic test for correlated proportions [<xref ref-type="bibr" rid="CR22">22</xref>]. We provide an Excel file (Microsoft, Redmond, WA, USA) that allows the assessment of NRI with its standard error and its <italic>P</italic>-value [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>All resulting <italic>P</italic>-values were two-tailed, and <italic>P</italic>&#x02009;&#x02264;&#x02009;0.05 was considered statistically significant. Statistical analyses were performed using STATA version 10 and SAS version 9.2 (SAS Institute, Cary, NC, USA).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>In this study, we enrolled a total of 367 participants who received a lumbar puncture between 1 September 2012 and 1 September 2013. The study was conducted at three study centers (Paris, n&#x02009;=&#x02009;82 subjects; Lille, n&#x02009;=&#x02009;124 subjects; Montpellier, n&#x02009;=&#x02009;161 subjects). The subjects&#x02019; characteristics are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Compared with non-AD subjects, participants with AD were older, were more likely to be female and had lower Mini Mental State Examination scores. Furthermore, subjects with AD had higher CSF tau and p-tau181 levels, lower CSF A&#x003b2;42 levels and lower CSF A&#x003b2; 42/40 ratios. CSF A&#x003b2;40 levels tended to be higher in patients with AD compared with non-AD patients (<italic>P</italic>&#x02009;=&#x02009;0.06), but this relationship was attenuated after adjustment for age and sex (<italic>P</italic>&#x02009;=&#x02009;0.19).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Characteristics of the study population</bold>
<sup><bold>a</bold></sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Characteristics</bold>
</th><th>
<bold>Overall (N&#x02009;=&#x02009;367)</bold>
</th><th>
<bold>AD (n&#x02009;=&#x02009;160)</bold>
</th><th>
<bold>Non-AD (n&#x02009;=&#x02009;207)</bold>
</th><th>
<bold><italic>P</italic></bold>
<bold>-value</bold>
<sup><bold>b</bold></sup>
</th></tr></thead><tbody><tr valign="top"><td>Age (yr), mean (SD)</td><td>65.9 (10.7)</td><td>67.9 (9.7)</td><td>64.5 (11.2)</td><td>0.002</td></tr><tr valign="top"><td>Women, n (%)</td><td>190 (51.9)</td><td>97 (60.6)</td><td>93 (45.2)</td><td>0.003</td></tr><tr valign="top"><td>MMSE, mean (SD)</td><td>22.2 (61.1)</td><td>20.3 (6.1)</td><td>23.6 (5.6)</td><td>&#x0003c;0.001</td></tr><tr valign="top"><td>CSF biomarkers (pg/ml), mean (SD)</td><td/><td/><td/><td/></tr><tr valign="top"><td>Total tau</td><td>445.4 (334.8)</td><td>660.5 (349.5)</td><td>279.2 (202.9)</td><td>&#x0003c;0.001</td></tr><tr valign="top"><td>pTau-181</td><td>62.8 (37.2)</td><td>89.7 (38.7)</td><td>42.0 (17.6)</td><td>&#x0003c;0.001</td></tr><tr valign="top"><td>A&#x003b2;42</td><td>863.6 (357.3)</td><td>668.5 (297.3)</td><td>1,014.5 (325.9)</td><td>&#x0003c;0.001</td></tr><tr valign="top"><td>A&#x003b2;40</td><td>15,426.6 (8,630.6)</td><td>16,383.6 (8,761.3)</td><td>14,686.9 (8,475.4)</td><td>0.06</td></tr><tr valign="top"><td>A&#x003b2; 42/40</td><td>0.068 (0.047)</td><td>0.047 (0.022)</td><td>0.084 (0.054)</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>A&#x003b2;, Amyloid-beta; AD, Alzheimer&#x02019;s disease; CSF, Cerebrospinal fluid; MMSE, Mini Mental State Examination; SD, Standard deviation. <sup>b</sup>By &#x003c7;<sup>2</sup> test or analysis of variance.</p></table-wrap-foot></table-wrap></p><p>The percentages of patients with AD across centers ranged from 31% to 59% (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). There were no significant differences in age or sex between AD and non-AD patients across the three sites. In patients with AD, the A&#x003b2; 42/40 ratio was the only comparable biomarker between the three sites, with a mean value ranging from 4.4% to 4.9% (<italic>P</italic>&#x02009;=&#x02009;0.39).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Intercenter characteristics</bold>
<sup><bold>a</bold></sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th colspan="3">
<bold>Characteristics</bold>
</th><th>
<bold>Center 1 (N&#x02009;=&#x02009;82)</bold>
</th><th>
<bold>Center 2 (n&#x02009;=&#x02009;124)</bold>
</th><th>
<bold>Center 3 (n&#x02009;=&#x02009;161)</bold>
</th><th align="left">
<bold><italic>P</italic></bold>
<bold>-value</bold>
<sup><bold>b</bold></sup>
</th></tr></thead><tbody><tr valign="top"><td colspan="3">
<bold>AD patients</bold>
</td><td/><td/><td/><td/></tr><tr valign="top"><td/><td colspan="2">Number of subjects (%)</td><td>37 (45.1)</td><td>73 (58.9)</td><td>50 (31.1)</td><td align="left">&#x0003c;0.001</td></tr><tr valign="top"><td/><td colspan="2">Age (yr), mean (SD)</td><td>68.9 (8.6)</td><td>67.0 (9.5)</td><td>68.5 (10.7)</td><td>0.54</td></tr><tr valign="top"><td/><td colspan="2">Women, n (%)</td><td>27 (73.0)</td><td>39 (53.4)</td><td>31 (62.0)</td><td>0.14</td></tr><tr valign="top"><td/><td colspan="2">MMSE, mean (SD)</td><td>18.6 (6.5)</td><td>19.5 (6.3)</td><td>22.8 (4.9)</td><td>0.003</td></tr><tr valign="top"><td/><td colspan="2">CSF biomarkers, pg/ml, mean (SD)</td><td/><td/><td/><td/></tr><tr valign="top"><td/><td/><td>Total tau</td><td>599.5 (281.2)</td><td>774.2 (370.7)</td><td>539.6 (315.2)</td><td align="left">&#x0003c;0.001</td></tr><tr valign="top"><td/><td/><td>p-tau181</td><td>79.4 (24.4)</td><td>101.5 (42.2)</td><td>80.0 (39.2)</td><td>0.002</td></tr><tr valign="top"><td/><td/><td>A&#x003b2;42</td><td>656.9 (257.1)</td><td>603.2 (245.4)</td><td>772.5 (363.5)</td><td>0.008</td></tr><tr valign="top"><td/><td/><td>A&#x003b2;40</td><td>16,229.7 (6,252.8)</td><td>13,426.8 (5,250.9)</td><td>20,814.3 (12,114.6)</td><td align="left">&#x0003c;0.001</td></tr><tr valign="top"><td/><td/><td>A&#x003b2; 42/40</td><td>0.044 (0.018)</td><td>0.049 (0.021)</td><td>0.045 (0.025)</td><td>0.39</td></tr><tr valign="top"><td colspan="3">
<bold>Non-AD patients</bold>
</td><td/><td/><td/><td/></tr><tr valign="top"><td/><td colspan="2">Number of subjects (%)</td><td>45 (54.9)</td><td>51 (41.1)</td><td>111 (68.9)</td><td align="left">&#x0003c;0.001</td></tr><tr valign="top"><td/><td colspan="2">Age (yr), mean (SD)</td><td>63.3 (10.7)</td><td>64.4 (10.6)</td><td>65.0 (11.8)</td><td>0.70</td></tr><tr valign="top"><td/><td colspan="2">Women, n (%)</td><td>17 (37.8)</td><td>20 (40.0)</td><td>56 (50.4)</td><td>0.25</td></tr><tr valign="top"><td/><td colspan="2">MMSE, mean (SD)</td><td>23.7 (4.9)</td><td>20.9 (6.1)</td><td>24.7 (5.3)</td><td align="left">&#x0003c;0.001</td></tr><tr valign="top"><td/><td colspan="2">CSF biomarkers (pg/ml), mean (SD)</td><td/><td/><td/><td/></tr><tr valign="top"><td/><td/><td>Total tau</td><td>201.5 (64.0)</td><td>283.8 (150.5)</td><td>308.6 (248.6)</td><td>0.01</td></tr><tr valign="top"><td/><td/><td>p-tau181</td><td>40.4 (12.8)</td><td>46.2 (15.8)</td><td>40.8 (19.7)</td><td>0.14</td></tr><tr valign="top"><td/><td/><td>A&#x003b2;42</td><td>984.3 (253.6)</td><td>987.0 (344.7)</td><td>1,039.3 (343.3)</td><td>0.50</td></tr><tr valign="top"><td/><td/><td>A&#x003b2;40</td><td>12,219.5 (4,775.2)</td><td>11,161.0 (4,955.5)</td><td>17307.2 (9,952.7)</td><td align="left">&#x0003c;0.001</td></tr><tr valign="top"><td/><td/><td>A&#x003b2; 42/40</td><td>0.087 (0.024)</td><td>0.098 (0.041)</td><td>0.077 (0.066)</td><td>0.06</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>A&#x003b2;, Amyloid-beta; AD, Alzheimer&#x02019;s disease; CSF, Cerebrospinal fluid; MMSE, Mini Mental State Examination; p-tau181, tau phosphorylated at threonine 181; SD, Standard deviation. <sup>b</sup>By &#x003c7;<sup>2</sup> test or analysis of variance.</p></table-wrap-foot></table-wrap></p><p>The results of ROC curve analysis comparing AD with non-AD patients and optimum cutoffs are presented in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Area under the receiver operating characteristic curve (AUC) values for the various biomarkers can be used to discriminate between AD and non-AD patients. Across all three centers, tau (AUC range, 0.77 to 0.96) and p-tau181 levels (AUC range, 0.84 to 0.95) were more useful than A&#x003b2;42 levels (AUC range, 0.74 to 0.82) for AD diagnosis. A&#x003b2; 42/40 ratio outperformed A&#x003b2;42 in only one of the three centers, but not in the overall population (AUC&#x02009;=&#x02009;0.81). Optimum cutoffs for CSF A&#x003b2;42 and for A&#x003b2; 42/40 ratio ranged from 737 pg/ml to 836 pg/ml and from 0.050 to 0.082, respectively.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Area under the receiver operating characteristic curve and optimal value to discriminate subjects with Alzheimer&#x02019;s disease from those without</bold>
<sup><bold>a</bold></sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th colspan="2">
<bold>CSF biomarkers, pg/ml</bold>
</th><th>
<bold>AUC (SE)</bold>
</th><th>
<bold>Optimal value</bold>
</th><th>
<bold>Sensitivity</bold>
</th><th>
<bold>Specificity</bold>
</th><th align="left">
<bold>Youden index</bold>
</th></tr></thead><tbody><tr valign="top"><td colspan="2">Overall</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td/><td>Total tau</td><td>0.87 (0.02)</td><td char="." align="char">330</td><td>0.84</td><td char="." align="char">0.81</td><td>0.65</td></tr><tr valign="top"><td/><td>p-tau181</td><td>0.90 (0.02)</td><td char="." align="char">62</td><td>0.79</td><td char="." align="char">0.91</td><td>0.70</td></tr><tr valign="top"><td/><td>A&#x003b2;42</td><td>0.81 (0.02)</td><td char="." align="char">752</td><td>0.78</td><td char="." align="char">0.79</td><td>0.57</td></tr><tr valign="top"><td/><td>A&#x003b2; 42/40</td><td>0.81 (0.02)</td><td char="." align="char">0.055</td><td>0.73</td><td char="." align="char">0.78</td><td>0.51</td></tr><tr valign="top"><td colspan="2">Center 1</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td/><td>Total tau</td><td>0.96 (0.01)</td><td char="." align="char">300</td><td>0.95</td><td char="." align="char">0.96</td><td>0.91</td></tr><tr valign="top"><td/><td>pTau-181</td><td>0.95 (0.02)</td><td char="." align="char">58</td><td>0.86</td><td char="." align="char">0.91</td><td>0.77</td></tr><tr valign="top"><td/><td>A&#x003b2;42</td><td>0.81 (0.05)</td><td char="." align="char">814</td><td>0.84</td><td char="." align="char">0.80</td><td>0.64</td></tr><tr valign="top"><td/><td>A&#x003b2; 42/40</td><td>0.93 (0.03)</td><td char="." align="char">0.065</td><td>0.89</td><td char="." align="char">0.84</td><td>0.73</td></tr><tr valign="top"><td colspan="2">Center 2</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td/><td>Total tau</td><td>0.91 (0.03)</td><td char="." align="char">389</td><td>0.86</td><td char="." align="char">0.82</td><td>0.68</td></tr><tr valign="top"><td/><td>p-tau181</td><td>0.91 (0.03)</td><td char="." align="char">64</td><td>0.85</td><td char="." align="char">0.86</td><td>0.71</td></tr><tr valign="top"><td/><td>A&#x003b2;42</td><td>0.82 (0.04)</td><td char="." align="char">836</td><td>0.90</td><td char="." align="char">0.71</td><td>0.61</td></tr><tr valign="top"><td/><td>A&#x003b2; 42/40</td><td>0.87 (0.03)</td><td char="." align="char">0.082</td><td>0.90</td><td char="." align="char">0.67</td><td>0.57</td></tr><tr valign="top"><td colspan="2">Center 3</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td/><td>Total tau</td><td>0.77 (0.04)</td><td char="." align="char">343</td><td>0.74</td><td char="." align="char">0.77</td><td>0.51</td></tr><tr valign="top"><td/><td>p-tau181</td><td>0.84 (0.04)</td><td char="." align="char">62</td><td>0.72</td><td char="." align="char">0.92</td><td>0.64</td></tr><tr valign="top"><td/><td>A&#x003b2;42</td><td>0.74 (0.05)</td><td char="." align="char">737</td><td>0.70</td><td char="." align="char">0.80</td><td>0.50</td></tr><tr valign="top"><td/><td>A&#x003b2; 42/40</td><td>0.75 (0.04)</td><td char="." align="char">0.050</td><td>0.64</td><td char="." align="char">0.79</td><td>0.43</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>A&#x003b2;, Amyloid-beta; AUC, Area under the receiver operating characteristic curve; CSF, Cerebrospinal fluid; p-tau181, tau phosphorylated at threonine 181; SE, Standard error.</p></table-wrap-foot></table-wrap></p><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> illustrates the results of CSF biomarkers in the overall population according to CSF A&#x003b2;42 and CSF p-tau181 and per the global cutoffs based on the previous ROC curve analysis (overall population study). A total of 284 patients (77%) had determinate and definitive results using CSF A&#x003b2;<sub>1&#x02013;42</sub> and CSF p-tau181 levels (non-AD profile or AD-type profile), and 83 participants (23%) had indeterminate CSF results.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Scatterplot of cerebrospinal fluid amyloid-&#x003b2;42 and phosphorylated tau values in the overall study population.</bold> Black dots represent non-ambiguous cerebrospinal fluid (CSF) results (non-Alzheimer&#x02019;s disease (non-AD) in the upper left quadrant, AD in the lower right quadrant). Gray dots represent indeterminate CSF results. Cutoffs for amyloid-&#x003b2;<sub>42</sub> (A&#x003b2;42) and phosphorylated tau (p-tau181) were calculated in the overall population. Among the 367 patients, 83 (23%) had indeterminate CSF results.</p></caption><graphic xlink:href="13195_2015_114_Fig1_HTML" id="MO1"/></fig></p><p>Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> illustrates the biological interpretation of CSF results according to three methods. (1) Interpretation based on CSF p-tau181 and CSF A&#x003b2;42 cutoffs (method 1) leads to 82 patients (22.3%) with indeterminate results. (2) Using CSF p-tau181 and A&#x003b2; 42/40 ratio (method 2) could reduce the number of indeterminate profiles to 64 patients (17.4%; <italic>P</italic>&#x02009;=&#x02009;0.03 compared with method 1). (3) Use of CSF p-tau181 and CSF A&#x003b2;42, and then A&#x003b2; 42/40 ratio in case of discrepancy (method 3), attenuated the number of indeterminate results to 38 patients (10.4%; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 compared with method 1).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Biological interpretation of cerebrospinal fluid results according to different methods.</bold> Method 1: Cerebrospinal fluid (CSF) phosphorylated tau (p-tau181) and CSF amyloid-&#x003b2;<sub>42</sub> (A&#x003b2;42). Method 2: CSF p-tau181 and A&#x003b2; 42/40 ratio. Method 3: First measure p-tau181 and CSF A&#x003b2;42, then use of A&#x003b2; 42/40 ratio instead of A&#x003b2;42 in case of discrepancy. Proportions of indeterminate profiles according to the methods were compared using the McNemar test.</p></caption><graphic xlink:href="13195_2015_114_Fig2_HTML" id="MO2"/></fig></p><p>Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> presents reclassification tables, comparing method 1 with methods 2 and 3 in patients with AD and non-AD patients. The systematic use of A&#x003b2; 42/40 ratio did not improve the classification of patients and tended even to be slightly worse than CSF A&#x003b2;42 alone with a NRI equal to &#x02212;2.1% (standard error (SE)&#x02009;=&#x02009;0.05, <italic>P</italic>&#x02009;=&#x02009;0.64). By contrast, the use of A&#x003b2; 42/40 ratio only in patients with discordant results between p-tau181 and A&#x003b2;42 (method 3) improved the classification of patients, with a NRI at 10.5% (SE&#x02009;=&#x02009;0.04, <italic>P</italic>&#x02009;=&#x02009;0.003) compared with method 1.<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Reclassification tables of different methods of cerebrospinal fluid interpretation among patients with Alzheimer&#x02019;s disease and non-Alzheimer&#x02019;s disease patients.</bold> Method 1 (reference): cerebrospinal fluid (CSF) phosphorylated tau (p-tau181) and CSF amyloid-&#x003b2;<sub>42</sub> (A&#x003b2;42). Method 2: CSF p-tau181 and A&#x003b2; 42/40 ratio. Method 3: First measure p-tau181 and CSF A&#x003b2; 42, then use A&#x003b2; 42/40 ratio instead of A&#x003b2;42 in case of discrepancy. Cells in green indicate an improvement compared with method 1, and cells in red indicate a worsening.</p></caption><graphic xlink:href="13195_2015_114_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>In this clinically based, multicenter study, we evaluated the systematic assessment of CSF A&#x003b2;40 as part of a battery of CSF biomarkers measured in patients with cognitive disorders. We made the following observations:<list list-type="bullet"><list-item><p>The A&#x003b2; 42/40 ratio was the only biomarker that was consistent between centers in AD and non-AD patients. We may therefore hypothesize that this ratio is less sensitive to preanalytical and analytical conditions.</p></list-item><list-item><p>The systematic use of A&#x003b2; 42/40 ratio instead of A&#x003b2;42 decreased the number of indeterminate CSF profiles but failed to improve the classification of patients based on clinical diagnosis (NRI&#x02009;=&#x02009;&#x02212;2.1%, <italic>P</italic>&#x02009;=&#x02009;0.64).</p></list-item><list-item><p>A strategy based on the use of A&#x003b2; 42/40 ratio instead of A&#x003b2;42 in patients with initially discrepant results between p-tau181 and A&#x003b2;42 led to a reduction of the number of indeterminate CSF profiles (10% vs. 22%) and improved the classification of patients (NRI&#x02009;=&#x02009;10.5%, <italic>P</italic>&#x02009;=&#x02009;0.003).</p></list-item></list></p><p>Consequently, the assessment of A&#x003b2; 42/40 ratio could be helpful and can be recommended as a second step when the initial CSF profile remains indeterminate.</p><p>Researchers in several previous studies have investigated the use of A&#x003b2; 42/40 ratio to differentiate patients with AD from patients with other cognitive disorders, and the reported results are heterogeneous. In a previous study, researchers found that A&#x003b2; 42/40 ratio outperformed A&#x003b2;42 alone in differentiating AD from non-AD patients, but the diagnostic performance of the combination of CSF tau and CSF A&#x003b2;42 was not improved by the use of A&#x003b2; 42/40 ratio instead of A&#x003b2;42 alone [<xref ref-type="bibr" rid="CR15">15</xref>]. In another study, using a subset of autopsy-confirmed diagnoses, investigators found no overall difference in AUC between A&#x003b2; 42/40 ratio and A&#x003b2;42 alone to differentiate AD from non-AD patients. Those authors showed that the use of A&#x003b2; 42/40 ratio improved diagnostic accuracy in patients with intermediate levels of phosphorylated tau [<xref ref-type="bibr" rid="CR12">12</xref>]. In other previous studies, researchers also found that the assessment of CSF A&#x003b2;40 may help to discriminate between AD patients and patients with frontotemporal lobar degeneration [<xref ref-type="bibr" rid="CR25">25</xref>] or dementia with Lewy bodies [<xref ref-type="bibr" rid="CR26">26</xref>] and Parkinson&#x02019;s disease with dementia [<xref ref-type="bibr" rid="CR27">27</xref>]. In contrast, the authors of another previous report found that the diagnostic accuracy of CSF A&#x003b2;42 was not different from the A&#x003b2; 42/40 ratio to discriminate AD patients from control subjects [<xref ref-type="bibr" rid="CR14">14</xref>]. Controversial data have also been reported in patients with MCI, with some studies revealing that the A&#x003b2; 42/40 ratio may be useful to predict dementia conversion [<xref ref-type="bibr" rid="CR28">28</xref>], whereas another did not [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Our findings confirm and strengthen the results of a recent study in which researchers reported that the use of the A&#x003b2; 42/40 ratio may contribute to decreases in the proportion of indeterminate CSF profiles in the clinical setting [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>The proportion of patients with AD varied greatly at the three centers, reflecting the differences in recruitment and practices of memory clinics. Despite significant intercenter differences in reporting CSF A&#x003b2;40 and CSF A&#x003b2;42 levels, the mean A&#x003b2; 42/40 ratios were comparable across the three centers, ranging from 0.044 to 0.049 in patients with AD. We therefore hypothesize that the use of the CSF amyloid ratio could contribute to decreased preanalytical and analytical sources of variability among centers. Interestingly, we found that optimal cutoff for the ratio in the overall study population was equal to 0.055, which was comparable to the 0.057 cutoff recently reported by another team in a monocentric study [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Very few data are available concerning indeterminate profiles of CSF biomarkers. In our study population, on the basis of routine clinical practice, this situation was not rare, being observed in 22% of the patients even after optimization procedures using local optimum cutoffs. We have shown that A&#x003b2; 42/40 ratio instead of A&#x003b2;42 leads to a clear biological conclusion in more than 50% of these indeterminate cases. Reclassification analyses also showed that this approach is more congruent with the diagnosis by clinicians.</p><p>This study has several strengths, including its large size, its multicentric and prospective design, and the use of a common CSF polypropylene tubing at each of the three centers to standardize CSF evaluation. In addition, we used a NRI method that compares different strategies of biomarker analyses and is more precise than traditional analyses based on ROC curves. The main limitation of the results is the lack of neuropathological validations. Also, clinicians were not blinded to CSF results prior to clinical diagnosis, which may generate a circular reasoning bias in our findings. The absence of a centralized measurement for CSF biomarkers is another limitation, owing to the persistence of an intersite variability despite the use of a common tubing to collect CSF. Furthermore, the non-AD group was heterogeneous and included patients with cognitive disorders, of both psychiatric and neurologic origins. However, our study was aimed at reflecting the standard practice at memory clinics. The wide variety of patients with a number of diseases reflects the broad spectrum of cognitive complaints referred to memory centers. Finally, this study excluded patients with MCI. Inclusion of these patients in future studies will help to determine the links between the amyloid ratio and the rate of conversion from MCI to AD.</p></sec><sec id="Sec9" sec-type="conclusion"><title>Conclusions</title><p>Using a large prospective multicenter cohort of patients with cognitive disorders, we did not find an added value for the systematic assessment of the CSF A&#x003b2; 42/40 ratio. However, in cases of discrepancy between CSF p-tau and CSF A&#x003b2;42, the use of A&#x003b2; 42/40 ratio allowed reaching a biological conclusion in more than 50% of indeterminate results and improved the biological congruence with clinical diagnoses.</p></sec></body><back><app-group><app id="App1"><sec id="Sec10"><title>Additional files</title><p><media position="anchor" xlink:href="13195_2015_114_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>
<bold>List of local ethics committees that approved the research study.</bold>
</p></caption></media><media position="anchor" xlink:href="13195_2015_114_MOESM2_ESM.docx" id="MOESM2"><label>Additional file 2:</label><caption><p>
<bold>STATA code used for determination of local optimum cutoffs.</bold>
</p></caption></media><media position="anchor" xlink:href="13195_2015_114_MOESM3_ESM.docx" id="MOESM3"><label>Additional file 3:</label><caption><p>
<bold>Characteristics of non-AD patients.</bold>
</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AD</term><def><p>Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>A&#x003b2;</term><def><p>Amyloid-&#x003b2; protein</p></def></def-item><def-item><term>A&#x003b2;40</term><def><p>40&#x02013;amino acid isoform of amyloid-&#x003b2; protein</p></def></def-item><def-item><term>A&#x003b2;42</term><def><p>42&#x02013;amino acid isoform of amyloid-&#x003b2; protein</p></def></def-item><def-item><term>AUC</term><def><p>Area under the receiver operating characteristic curve</p></def></def-item><def-item><term>CSF</term><def><p>Cerebrospinal fluid</p></def></def-item><def-item><term>MCI</term><def><p>Mild cognitive impairment</p></def></def-item><def-item><term>MMSE</term><def><p>Mini Mental State Examination</p></def></def-item><def-item><term>NRI</term><def><p>Net reclassification improvement</p></def></def-item><def-item><term>p-tau181</term><def><p>tau phosphorylated at threonine 181</p></def></def-item><def-item><term>ROC</term><def><p>Receiver operating characteristic</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>SE</term><def><p>Standard error</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>JD processed and analyzed the data, prepared the results presentation and drafted various versions of the manuscript. SS participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). AG participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). OV participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). SB participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). JLL participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). KP participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). BS participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). KVK participated in the research project (interpretation of data, execution) and in manuscript preparation (review and critique). CD participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). FP participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). JT participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). JH participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique) and helped draft the manuscript. CP participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique) and helped draft the manuscript. SL helped with data analysis, participated in the research project (conception, organization, execution) and in manuscript preparation (review and critique). All authors edited and approved the final version of the manuscript.</p></fn></fn-group><ack><p>The authors thank the other members of the teams for their contributions to this study: Dr Florence Lebert, Dr Marie-Anne Mackowiak, Dr Vincent Deramecourt, Dr Adeline Rollin-Sillaire, Dr Pascaline Cassagnaud, Dr Karim Bennys, Dr Christian Geny, Dr Eric Thouvenot, Dr Sarah Benisty, Dr Val&#x000e9;rie Ducasse, Dr Claire Kiffel and all the neuropsychologists. The authors warmly thank Professors Jo&#x000eb;l M&#x000e9;nard, Herv&#x000e9; Maisonneuve, Jean Marie Goehrs and Patrick Trunet for their very helpful advice and for revising the manuscript. The authors also thank Sylvie Ledoux and the Fondation Plan Alzheimer for logistic support.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prince</surname><given-names>M</given-names></name><name><surname>Bryce</surname><given-names>R</given-names></name><name><surname>Albanese</surname><given-names>E</given-names></name><name><surname>Wimo</surname><given-names>A</given-names></name><name><surname>Ribeiro</surname><given-names>W</given-names></name><name><surname>Ferri</surname><given-names>CP</given-names></name></person-group><article-title>The global prevalence of dementia: a systematic review and metaanalysis</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><fpage>63&#x02013;75.e2.</fpage><pub-id pub-id-type="doi">10.1016/j.jalz.2012.11.007</pub-id><pub-id pub-id-type="pmid">23305823</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>GM</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Kawas</surname><given-names>CH</given-names></name><etal/></person-group><article-title>The diagnosis of dementia due to Alzheimer&#x02019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x02019;s Association workgroups on diagnostic guidelines for Alzheimer&#x02019;s disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>263</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmid">21514250</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Monsell</surname><given-names>SE</given-names></name><name><surname>Phillips</surname><given-names>LE</given-names></name><name><surname>Kukull</surname><given-names>W</given-names></name></person-group><article-title>Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005&#x02013;2010</article-title><source>J Neuropathol Exp Neurol</source><year>2012</year><volume>71</volume><fpage>266</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e31824b211b</pub-id><pub-id pub-id-type="pmid">22437338</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouton-Liger</surname><given-names>F</given-names></name><name><surname>Wallon</surname><given-names>D</given-names></name><name><surname>Troussi&#x000e8;re</surname><given-names>AC</given-names></name><name><surname>Yatimi</surname><given-names>R</given-names></name><name><surname>Dumurgier</surname><given-names>J</given-names></name><name><surname>Magnin</surname><given-names>E</given-names></name><etal/></person-group><article-title>Impact of cerebro-spinal fluid biomarkers of Alzheimer&#x02019;s disease in clinical practice: a multicentric study</article-title><source>J Neurol</source><year>2014</year><volume>261</volume><fpage>144</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s00415-013-7160-3</pub-id><pub-id pub-id-type="pmid">24162039</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ros&#x000e9;n</surname><given-names>C</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Fluid biomarkers in Alzheimer&#x02019;s disease - current concepts</article-title><source>Mol Neurodegener</source><year>2013</year><volume>8</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-8-20</pub-id><pub-id pub-id-type="pmid">23800368</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Xiong</surname><given-names>C</given-names></name><name><surname>Benzinger</surname><given-names>TL</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Clinical and biomarker changes in dominantly inherited Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>795</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1202753</pub-id><pub-id pub-id-type="pmid">22784036</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumurgier</surname><given-names>J</given-names></name><name><surname>Vercruysse</surname><given-names>O</given-names></name><name><surname>Paquet</surname><given-names>C</given-names></name><name><surname>Bombois</surname><given-names>S</given-names></name><name><surname>Chaulet</surname><given-names>C</given-names></name><name><surname>Laplanche</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Intersite variability of CSF Alzheimer&#x02019;s disease biomarkers in clinical setting</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><fpage>406</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2012.06.006</pub-id><pub-id pub-id-type="pmid">23141384</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumurgier</surname><given-names>J</given-names></name><name><surname>Laplanche</surname><given-names>JL</given-names></name><name><surname>Mouton-Liger</surname><given-names>F</given-names></name><name><surname>Lapalus</surname><given-names>P</given-names></name><name><surname>Indart</surname><given-names>S</given-names></name><name><surname>Pr&#x000e9;vot</surname><given-names>M</given-names></name><etal/></person-group><article-title>The screening of Alzheimer&#x02019;s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials</article-title><source>J Neurol</source><year>2014</year><volume>261</volume><fpage>1187</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s00415-014-7335-6</pub-id><pub-id pub-id-type="pmid">24728335</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Persson</surname><given-names>S</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name><name><surname>Chalbot</surname><given-names>S</given-names></name><etal/></person-group><article-title>CSF biomarker variability in the Alzheimer&#x02019;s Association quality control program</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><fpage>251</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2013.01.010</pub-id><pub-id pub-id-type="pmid">23622690</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>H&#x000fc;ll</surname><given-names>M</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Kessler</surname><given-names>H</given-names></name><etal/></person-group><article-title>Amyloid &#x003b2; peptide ratio 42/40 but not A&#x003b2;42 correlates with phospho-Tau in patients with low- and high-CSF A&#x003b2;40 load</article-title><source>J Neurochem</source><year>2007</year><volume>101</volume><fpage>1053</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04404.x</pub-id><pub-id pub-id-type="pmid">17254013</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name></person-group><article-title>Twenty years of the Alzheimer&#x02019;s disease amyloid hypothesis: a genetic perspective</article-title><source>Cell</source><year>2005</year><volume>120</volume><fpage>545</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.02.008</pub-id><pub-id pub-id-type="pmid">15734686</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slaets</surname><given-names>S</given-names></name><name><surname>Le Bastard</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>JJ</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid A&#x003b2;<sub>1-40</sub> improves differential dementia diagnosis in patients with intermediate P-tau<sub>181P</sub> levels</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>36</volume><fpage>759</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">23666174</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Chiasserini</surname><given-names>D</given-names></name><name><surname>Eusebi</surname><given-names>P</given-names></name><name><surname>Giannandrea</surname><given-names>D</given-names></name><name><surname>Bellomo</surname><given-names>G</given-names></name><name><surname>De Carlo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Performance of A&#x003b2;<sub>1-40</sub>, A&#x003b2;<sub>1-42</sub>, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>29</volume><fpage>229</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">22232006</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoonenboom</surname><given-names>NS</given-names></name><name><surname>Mulder</surname><given-names>C</given-names></name><name><surname>Van Kamp</surname><given-names>GJ</given-names></name><name><surname>Mehta</surname><given-names>SP</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Blankenstein</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Amyloid &#x003b2; 38, 40, and 42 species in cerebrospinal fluid: more of the same?</article-title><source>Ann Neurol</source><year>2005</year><volume>58</volume><fpage>139</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/ana.20508</pub-id><pub-id pub-id-type="pmid">15984010</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spies</surname><given-names>PE</given-names></name><name><surname>Slats</surname><given-names>D</given-names></name><name><surname>Sj&#x000f6;gren</surname><given-names>JM</given-names></name><name><surname>Kremer</surname><given-names>BP</given-names></name><name><surname>Verhey</surname><given-names>FR</given-names></name><name><surname>Rikkert</surname><given-names>MG</given-names></name><etal/></person-group><article-title>The cerebrospinal fluid amyloid &#x003b2;42/40 ratio in the differentiation of Alzheimer&#x02019;s disease from non-Alzheimer&#x02019;s dementia</article-title><source>Curr Alzheimer Res</source><year>2010</year><volume>7</volume><fpage>470</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2174/156720510791383796</pub-id><pub-id pub-id-type="pmid">20043812</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauv&#x000e9;e</surname><given-names>M</given-names></name><name><surname>DidierLaurent</surname><given-names>G</given-names></name><name><surname>Latarche</surname><given-names>C</given-names></name><name><surname>Escany&#x000e9;</surname><given-names>MC</given-names></name><name><surname>Olivier</surname><given-names>JL</given-names></name><name><surname>Malaplate-Armand</surname><given-names>C</given-names></name></person-group><article-title>Additional use of A&#x003b2;<sub>42</sub>/A&#x003b2;<sub>40</sub> ratio with cerebrospinal fluid biomarkers P-tau and A&#x003b2;<sub>42</sub> increases the level of evidence of Alzheimer&#x02019;s disease pathophysiological process in routine practice</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>41</volume><fpage>377</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">24614902</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troussi&#x000e8;re</surname><given-names>AC</given-names></name><name><surname>Wallon</surname><given-names>D</given-names></name><name><surname>Mouton-Liger</surname><given-names>F</given-names></name><name><surname>Yatimi</surname><given-names>R</given-names></name><name><surname>Robert</surname><given-names>P</given-names></name><name><surname>Hugon</surname><given-names>J</given-names></name><etal/></person-group><article-title>Who needs cerebrospinal biomarkers? A national survey in clinical practice</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>40</volume><fpage>857</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">24577469</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabelle</surname><given-names>A</given-names></name><name><surname>Dumurgier</surname><given-names>J</given-names></name><name><surname>Vercruysse</surname><given-names>O</given-names></name><name><surname>Paquet</surname><given-names>C</given-names></name><name><surname>Bombois</surname><given-names>S</given-names></name><name><surname>Laplanche</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Impact of the 2008&#x02013;2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>34</volume><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">23186986</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumurgier</surname><given-names>J</given-names></name><name><surname>Gabelle</surname><given-names>A</given-names></name><name><surname>Vercruysse</surname><given-names>O</given-names></name><name><surname>Bombois</surname><given-names>S</given-names></name><name><surname>Laplanche</surname><given-names>JL</given-names></name><name><surname>Peoc&#x02019;h</surname><given-names>K</given-names></name><etal/></person-group><article-title>Exacerbated CSF abnormalities in younger patients with Alzheimer&#x02019;s disease</article-title><source>Neurobiol Dis</source><year>2013</year><volume>54</volume><fpage>486</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2013.01.023</pub-id><pub-id pub-id-type="pmid">23416172</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>S</given-names></name><name><surname>Dumurgier</surname><given-names>J</given-names></name><name><surname>Schraen</surname><given-names>S</given-names></name><name><surname>Wallon</surname><given-names>D</given-names></name><name><surname>Blanc</surname><given-names>F</given-names></name><name><surname>Magnin</surname><given-names>E</given-names></name><etal/></person-group><article-title>A diagnostic scale for Alzheimer&#x02019;s disease based on cerebrospinal fluid biomarker profiles</article-title><source>Alzheimers Res Ther</source><year>2014</year><volume>6</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/alzrt267</pub-id><pub-id pub-id-type="pmid">25478015</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>S</given-names></name><name><surname>Schraen</surname><given-names>S</given-names></name><name><surname>Quadrio</surname><given-names>I</given-names></name><name><surname>Paquet</surname><given-names>C</given-names></name><name><surname>Bombois</surname><given-names>S</given-names></name><name><surname>Delaby</surname><given-names>C</given-names></name><etal/></person-group><article-title>Impact of harmonization of collection tubes on Alzheimer&#x02019;s disease diagnosis</article-title><source>Alzheimers Dement</source><year>2014</year><volume>10</volume><issue>5 Suppl</issue><fpage>S390&#x02013;S394.e2</fpage><pub-id pub-id-type="pmid">24269268</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pencina</surname><given-names>MJ</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Jr</suffix></name><name><surname>Vasan</surname><given-names>RS</given-names></name></person-group><article-title>Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond</article-title><source>Stat Med</source><year>2008</year><volume>27</volume><fpage>157</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/sim.2929</pub-id><pub-id pub-id-type="pmid">17569110</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pencina</surname><given-names>MJ</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name></person-group><article-title>Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers</article-title><source>Stat Med</source><year>2011</year><volume>30</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/sim.4085</pub-id><pub-id pub-id-type="pmid">21204120</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Centre M&#x000e9;moire de Ressources et de Recherche, Paris Nord Ile-de-France. Net Reclassification Improvement (NRI) calculator. Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.parisnord.org/net-reclassification-improvement-excell-calculator.html">http://www.parisnord.org/net-reclassification-improvement-excell-calculator.html</ext-link>. Accessed 24 Mar 2015.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verwey</surname><given-names>NA</given-names></name><name><surname>Kester</surname><given-names>MI</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Veerhuis</surname><given-names>R</given-names></name><name><surname>Berkhof</surname><given-names>H</given-names></name><name><surname>Twaalfhoven</surname><given-names>H</given-names></name><etal/></person-group><article-title>Additional value of CSF amyloid-&#x003b2;<sub>40</sub> levels in the differentiation between FTLD and control subjects</article-title><source>J Alzheimers Dis</source><year>2010</year><volume>20</volume><fpage>445</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">20164558</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Lewczuk</surname><given-names>P</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Brechlin</surname><given-names>P</given-names></name><etal/></person-group><article-title>CSF diagnosis of Alzheimer&#x02019;s disease and dementia with Lewy bodies</article-title><source>J Neural Transm</source><year>2006</year><volume>113</volume><fpage>1771</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s00702-006-0537-z</pub-id><pub-id pub-id-type="pmid">16906356</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutu</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>N&#x000e4;gga</surname><given-names>K</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evaluation of the cerebrospinal fluid amyloid-&#x003b2;<sub>1-42</sub>/amyloid-&#x003b2;<sub>1-40</sub> ratio measured by &#x003b1;-LISA to distinguish Alzheimer&#x02019;s disease from other dementia disorders</article-title><source>Dement Geriatr Cogn Disord</source><year>2013</year><volume>36</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1159/000353442</pub-id><pub-id pub-id-type="pmid">23860354</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Buchhave</surname><given-names>P</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prediction of Alzheimer&#x02019;s disease using the CSF A&#x003b2;42/A&#x003b2;40 ratio in patients with mild cognitive impairment</article-title><source>Dement Geriatr Cogn Disord</source><year>2007</year><volume>23</volume><fpage>316</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1159/000100926</pub-id><pub-id pub-id-type="pmid">17374949</pub-id></element-citation></ref></ref-list></back></article>